Table 1.
Baseline Clinical Characteristics of Study Population (N=38)
| Characteristics | Results |
|---|---|
| Age of SSc onset mean ± SD (range), in years | 44.3 ± 11.4 (21-74) |
| Disease duration at ILD diagnosis mean ± SD (range), in years | 4.6 ± 4.6 (0-23) |
| Gender | |
| Female: Male, n (%) | 26 (68): 12 (32) |
| Race | |
| Caucasian, n (%) | 28 (74) |
| African American, n (%) | 7(18) |
| Other, n (%) | 3 (8) |
| Subtype | |
| lcSSc: dcSSc, n (%) | 16 (42): 22 (58) |
| Autoantibody Status | |
| positive ACA, n | 1 |
| positive anti-TPO, n | 18 |
| Baseline % predicted FVC, mean ± SD (range) | 63.3 ± 12.4 (39.4-95.5) |
| Baseline % predicted DLco, mean ± SD (range) | 52.6 ± 16.4 (26.2-102.1) |
| Follow-up period mean ± SD (range), in years | 5.1 ± 2.1 (2.3-10.8) |
| Duration of CYC therapy mean ± SD (range), in months | 20.3 ± 13.6 (6 months-6.7 years) |
Legend: ACA- anti-centromere antibody: 3 missing ; Anti-TPO-anti-topoisomerase antibody: 2 missing; SSc- systemicscleroderma; CYC-cyclophosphamide; FVC- forced vital capacity; DLco-single-breath carbon monoxide diffusing capacity; lcSSc- limited cutaneous scleroderma; dcSSc-diffuse cutaneous scleroderma.